Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer: A prospective single center study

Francesca Bagnasco, Riccardo Haupt, Vincenzo Fontana, Maria Grazia Valsecchi, Paola Rebora, Ilaria Caviglia, Silvia Caruso, Elio Castagnola

Research output: Contribution to journalArticle

Abstract

Background: Febrile neutropenia (FN) is a possible complication of antineoplastic chemotherapy. Aim of the study was to estimate the risk of developing fever at the beginning of any neutropenic period based on the previous history of FN. Procedure: The conditional frailty model was used to estimate the risk of developing fever during neutropenia separately for children with acute leukaemia/non-Hodgkin lymphoma (AL/NHL), or solid tumour (ST). The total number of previous FN episodes (PFNE), age, gender, type of tumour, calendar year of granulocytopenic period, phase of treatment, and granulocyte count were included in the model. Results: A total of 901 granulocytopenic periods was observed in 223 children: 306 in 66 AL/NHL and 595 in 157 ST. Fever developed in 328 cases: 125 in 53 AL/NHL and 203 in 92 ST. The PFNE variable was not significantly associated to the risk of fever [hazard ratio (HR) of 0.87, 95% confidence interval (CI) of 0.62-1.22 in children with AL/NHL, and HR of 0.98, 95% CI of 0.70-1.37 in those with ST]. The hazard of FN was significantly affected by the phase of treatment in AL/NHL (P

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalJournal of Chemotherapy
Volume24
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Agranulocytosis
Febrile Neutropenia
Non-Hodgkin's Lymphoma
Leukemia
Fever
Drug Therapy
Neoplasms
Confidence Intervals
Neutropenia
Granulocytes
Antineoplastic Agents
History
Therapeutics

Keywords

  • Discontinuous interval of risk
  • Epidemiology
  • Event dependence
  • Heterogeneity
  • Pediatric cancer
  • Repeated febrile neutropenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Cite this

Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer : A prospective single center study. / Bagnasco, Francesca; Haupt, Riccardo; Fontana, Vincenzo; Valsecchi, Maria Grazia; Rebora, Paola; Caviglia, Ilaria; Caruso, Silvia; Castagnola, Elio.

In: Journal of Chemotherapy, Vol. 24, No. 3, 06.2012, p. 155-160.

Research output: Contribution to journalArticle

@article{51cdb608f18746e58a20eae906c7bb62,
title = "Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer: A prospective single center study",
abstract = "Background: Febrile neutropenia (FN) is a possible complication of antineoplastic chemotherapy. Aim of the study was to estimate the risk of developing fever at the beginning of any neutropenic period based on the previous history of FN. Procedure: The conditional frailty model was used to estimate the risk of developing fever during neutropenia separately for children with acute leukaemia/non-Hodgkin lymphoma (AL/NHL), or solid tumour (ST). The total number of previous FN episodes (PFNE), age, gender, type of tumour, calendar year of granulocytopenic period, phase of treatment, and granulocyte count were included in the model. Results: A total of 901 granulocytopenic periods was observed in 223 children: 306 in 66 AL/NHL and 595 in 157 ST. Fever developed in 328 cases: 125 in 53 AL/NHL and 203 in 92 ST. The PFNE variable was not significantly associated to the risk of fever [hazard ratio (HR) of 0.87, 95{\%} confidence interval (CI) of 0.62-1.22 in children with AL/NHL, and HR of 0.98, 95{\%} CI of 0.70-1.37 in those with ST]. The hazard of FN was significantly affected by the phase of treatment in AL/NHL (P",
keywords = "Discontinuous interval of risk, Epidemiology, Event dependence, Heterogeneity, Pediatric cancer, Repeated febrile neutropenia",
author = "Francesca Bagnasco and Riccardo Haupt and Vincenzo Fontana and Valsecchi, {Maria Grazia} and Paola Rebora and Ilaria Caviglia and Silvia Caruso and Elio Castagnola",
year = "2012",
month = "6",
doi = "10.1179/1973947812Y.0000000002",
language = "English",
volume = "24",
pages = "155--160",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer

T2 - A prospective single center study

AU - Bagnasco, Francesca

AU - Haupt, Riccardo

AU - Fontana, Vincenzo

AU - Valsecchi, Maria Grazia

AU - Rebora, Paola

AU - Caviglia, Ilaria

AU - Caruso, Silvia

AU - Castagnola, Elio

PY - 2012/6

Y1 - 2012/6

N2 - Background: Febrile neutropenia (FN) is a possible complication of antineoplastic chemotherapy. Aim of the study was to estimate the risk of developing fever at the beginning of any neutropenic period based on the previous history of FN. Procedure: The conditional frailty model was used to estimate the risk of developing fever during neutropenia separately for children with acute leukaemia/non-Hodgkin lymphoma (AL/NHL), or solid tumour (ST). The total number of previous FN episodes (PFNE), age, gender, type of tumour, calendar year of granulocytopenic period, phase of treatment, and granulocyte count were included in the model. Results: A total of 901 granulocytopenic periods was observed in 223 children: 306 in 66 AL/NHL and 595 in 157 ST. Fever developed in 328 cases: 125 in 53 AL/NHL and 203 in 92 ST. The PFNE variable was not significantly associated to the risk of fever [hazard ratio (HR) of 0.87, 95% confidence interval (CI) of 0.62-1.22 in children with AL/NHL, and HR of 0.98, 95% CI of 0.70-1.37 in those with ST]. The hazard of FN was significantly affected by the phase of treatment in AL/NHL (P

AB - Background: Febrile neutropenia (FN) is a possible complication of antineoplastic chemotherapy. Aim of the study was to estimate the risk of developing fever at the beginning of any neutropenic period based on the previous history of FN. Procedure: The conditional frailty model was used to estimate the risk of developing fever during neutropenia separately for children with acute leukaemia/non-Hodgkin lymphoma (AL/NHL), or solid tumour (ST). The total number of previous FN episodes (PFNE), age, gender, type of tumour, calendar year of granulocytopenic period, phase of treatment, and granulocyte count were included in the model. Results: A total of 901 granulocytopenic periods was observed in 223 children: 306 in 66 AL/NHL and 595 in 157 ST. Fever developed in 328 cases: 125 in 53 AL/NHL and 203 in 92 ST. The PFNE variable was not significantly associated to the risk of fever [hazard ratio (HR) of 0.87, 95% confidence interval (CI) of 0.62-1.22 in children with AL/NHL, and HR of 0.98, 95% CI of 0.70-1.37 in those with ST]. The hazard of FN was significantly affected by the phase of treatment in AL/NHL (P

KW - Discontinuous interval of risk

KW - Epidemiology

KW - Event dependence

KW - Heterogeneity

KW - Pediatric cancer

KW - Repeated febrile neutropenia

UR - http://www.scopus.com/inward/record.url?scp=84866247062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866247062&partnerID=8YFLogxK

U2 - 10.1179/1973947812Y.0000000002

DO - 10.1179/1973947812Y.0000000002

M3 - Article

C2 - 22759760

AN - SCOPUS:84866247062

VL - 24

SP - 155

EP - 160

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -